ARWR: Arrowhead Research Corporation Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, April 30, 12:46 PM Midday top 10 gainers: TTHI +45%. PTIE +26%. DRRX +26%. MTOR +23%. MGAM +20%. OIS +16%. GIB +14%. HGSH +15%. ARWR +13%. TXRH +13%.
Midday top 10 losers: DCTH -44%. AVEO -26%. NUAN -18%. AOSL -18%. PBI -16%. AEIS -13%. MSTR -10%. ANV -10%. ELTK -10%. SYN -10%. Comment! [On the Move]
Monday, March 25, 9:10 AM Premarket gainers: ZAZA +21%. ARWR +14%. APOL +9%. TSRX +5%. Losers: IDIX -10%. OTT -10%. UTHR -7%. PGTI -6%. Comment! [On the Move]
Thursday, March 14, 9:25 AM Arrowhead Research (ARWR) +5.3% premarket after a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus supports findings from rodent models indicating it can knock down hepatitis B virus DNA and key viral antigens. Comment! [Healthcare, On the Move]
Thursday, March 14, 9:15 AM Premarket gainers: MW +15%. EBIX +14%. ARWR +8%. BLDP +6%. FTE +6%.
Losers: ANAD -8%. NBG -7%. DCTH -7%. ETFC -7%. VRA -6%. Comment! [On the Move]
Tuesday, February 26, 9:10 AM Premarket gainers: CWH +28%. ALC +22%. ARWR +17%. AXTI +8%. SPRD +7%. AUXL +6%. DCTH +5%.
Losers: TWI -10%. VVUS -7%. VSI -7%. EEQ -5%. 1 Comment [On the Move]
Friday, January 25, 1:39 PM Arrowhead Research (ARWR -7%) slides today after pricing its 1.65 million unit public offering at $2.12 per unit. Each unit consists of one share of common stock and one warrant to purchase 0.50 of a share of common. The company intends to use the net proceeds for general corporate purposes, including R&D and clinical trial expenditures, Comment! [On the Move]
Friday, January 25, 12:45 PM Midday top 10 gainers: EFII +15%. OSK +15%. SHIP +15%. SYNA +15%. LSCC +14%. NFLX +14%. QLGC +13%. BDR +13%. CIMT +13%. CRUS +12%.
Midday top 10 Losers: NFBK -27%. ZN -26%. SCSS -18%. SCSC -15%. BGMD -15%. CTRP -13%. HTCH -11%. EGHT -10%. ARWR -8%. MSL -7%. Comment! [On the Move]
Friday, January 25, 8:06 AM Two other biotechs undertaking secondary offerings today: Arrowhead Research (ARWR) off 6.5% premarket - and Anthera Pharmaceuticals (ANTH) - off 10% premarket. (Arrowhead PR). (Anthera PR). (BG Medicine earlier). Comment! [Healthcare, On the Move]
Tuesday, December 18, 2012, 12:17 PM Arrowhead Research (ARWR -6.8%) says it's signed a research collaboration and license agreement with Shire (SHPG +0.8%) to develop and commercialize targeted peptide-drug conjugates by utilizing ARWR's human-derived Homing Peptide platform and SHPG's therapeutic payloads. Arrowhead will receive research funding and could be eligible for milestone payments of up to $32.8M for each development candidate, plus additional milestone payments for a second indication, as well as royalties on worldwide sales. 2 Comments [Healthcare]
Wednesday, October 31, 2012, 12:45 PM Midday top 10 gainers: SHF +46%. WRC +37%. OPNT +29%. RRGB +25%. MPAC +23%. RCON +23%. HNSN +20%. CVLT +20%. ARWR +20%. GPRE +19%. Midday top 10 Losers: IQNT -35%. OXF -31%. BCRX -29%. WU -28%. PBIB -25%. CRNT -24%. CHRM -20%. CBAK -18%. RVBD -19%. NBG -18%. 2 Comments [On the Move]
Monday, August 13, 2012, 2:12 PM Shares of Arrowhead Research (ARWR -13.8%) hit a new 52-week low earlier in the session after the company says it's entered into a $6.2M securities purchase agreement with several institutional and individual investors, including James Mellon, and a new fund dedicated to health care investments. The placement consists of 2.3M shares of common stock, and warrants to purchase 1.7M shares, with each unit priced at $2.76 and consisting of one share of common stock and a warrant worth 0.75 shares. Comment! [Healthcare]

ARWR Arrowhead Research Corporation

ARWR

Arrowhead Research Corporation